Loading…
Loading…
NEW YORK and NEW ORLEANS, July 21, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. (“ADMA” or the “Company”) (NasdaqGM: ADMA) of a class action securities lawsuit.
The latest trading day saw Adma Biologics (ADMA) settling at $8.59, representing a -1.83% change from its previous close.
New York, New York--(Newsfile Corp. - July 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
BENSALEM, Pa., July 21, 2026 /PRNewswire/ -- The Law Offices of Howard G.
LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ADMA Biologics, Inc., (“ADMA” or the "Company") (NASDAQ: ADMA) investors of a class action on behalf of investors that bought securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”). ADMA investors have until August 10, 2026 to file a lead plaintiff motion.
Wall Street's reassessment of ADMA Biologics accelerated after a short-seller report alleged that the company's reported 20% ASCENIV revenue growth was entirely fictitious, driven by channel stuffing that masked a 3% decline. Wall Street's reassessment of ADMA Biologics accelerated after a short-seller report alleged that the company's reported 20% ASCENIV revenue growth was entirely fictitious, driven by channel stuffing that masked a 3% decline.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for ADMA and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.